Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.57 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MLNR | O43193 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29757864 | 1.00 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3GID4MEN1 | |
| SCHEMBL5029704 | 1.00 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3GID4MEN1 | |
| SCHEMBL8238524 | 1.00 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3GID4MEN1 | |
| Hydrochloric Acid SCHEMBL5955564 | 0.98 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3GID4MEN1 | |
| SCHEMBL5709376 | 0.90 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL6941770 | 0.87 | GID4 (0.56) | SLC6A2SLC6A4SLC6A3GID4CYP3A4 | |
| SCHEMBL20468142 | 0.87 | GID4 (0.56) | SLC6A2SLC6A4SLC6A3GID4CYP3A4 | |
| SCHEMBL20162486 | 0.83 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL20863599 | 0.82 | HAO1 (0.53) | SLC6A2SLC6A4SLC6A3GID4ADRA2A | |
| SCHEMBL22319970 | 0.79 | GID4 (0.61) | SLC6A2SLC6A4SLC6A3GID4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651590-A2 | PROCESS FOR THE PREPARATION OF AN IMINE INTERMEDIATE | EGIS GY GYSZERG (HU) | 2006-05-03 | — | — | EP | claimed |
| WO-2005007611-A2 | PROCESS FOR THE PREPARATION OF AN IMINE INTERMEDIATE | EGIS GYÓGYSZERGYÁR RT (HU) | 2005-01-27 | — | — | WO | claimed |
| WO-2023230308-A1 | DEGRADER COMPOUNDS OF QSOX1 mRNA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20200253996-A1 | TCTP INHIBITING AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | UNIVERSITE PARIS-SUD (FR) | 2020-08-13 | — | — | US | disclosed |
| US-20200253996-A1 | TCTP INHIBITING AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | UNIVERSITE PARIS-SUD (FR) | 2020-08-13 | — | — | US | disclosed |
| US-10611786-B2 | Manganese (III) catalyzed C—H aminations | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-04-07 | — | — | US | disclosed |
| WO-2019143920-A1 | ORAL DOSAGE FORMS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-11 | — | — | US | disclosed |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-11 | — | — | US | disclosed |
| WO-2019063955-A1 | AGENTS INHIBITING TCTP PROTEIN FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | UNIVERSITE PARIS-SUD (FR) | 2019-04-04 | — | — | WO | disclosed |
| WO-2018144385-A1 | ENAMIDE PROCESS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2008065177-A1 | PROCESSES FOR PREPARING DESMETHYLSERTRALINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CEREP (FR) | 2008-06-05 | — | — | WO | disclosed |
| EP-1904045-A1 | USE OF 4-(3,4-DICHLORO-PHENYL)-1,2,3,4-TETRAHYDRO-NAPHTALEN-1-YLAMINE FOR TREATING CANCER | Anceris (FR) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006797-A1 | USE OF 4-(3,4-DICHLORO-PHENYL)-1,2,3,4-TETRAHYDRO-NAPHTALEN-1-YLAMINE FOR TREATING CANCER | ANCERIS (FR) | 2007-01-18 | — | — | WO | disclosed |
| EP-1224159-B1 | IMPROVED SYNTHESIS OF RACEMIC SERTRALINE | GEA FARMACEUTISK FABRIK AS (DK) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253996-A1 | TCTP INHIBITING AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | NR3C1, TSLP, FPR3 | SLC6A2 3339/4885SLC6A4 2672/4885SLC6A3 2924/4885 |
| US-10611786-B2 | Manganese (III) catalyzed C—H aminations | HLCS, NCL, NUDC | SLC6A2 2679/4885SLC6A4 4361/4885SLC6A3 3409/4885 |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | HLCS, NCL, NUDC | SLC6A2 2459/4885SLC6A4 4130/4885SLC6A3 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.